ATE457729T1 - Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie - Google Patents

Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie

Info

Publication number
ATE457729T1
ATE457729T1 AT07729768T AT07729768T ATE457729T1 AT E457729 T1 ATE457729 T1 AT E457729T1 AT 07729768 T AT07729768 T AT 07729768T AT 07729768 T AT07729768 T AT 07729768T AT E457729 T1 ATE457729 T1 AT E457729T1
Authority
AT
Austria
Prior art keywords
allopurinol
treatment
palmar
erythrodysaesthesia
plantar
Prior art date
Application number
AT07729768T
Other languages
English (en)
Inventor
Yolanda Rodemer
Original Assignee
Nobera Pharma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06011432A external-priority patent/EP1862166A1/de
Application filed by Nobera Pharma Sl filed Critical Nobera Pharma Sl
Application granted granted Critical
Publication of ATE457729T1 publication Critical patent/ATE457729T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT07729768T 2006-06-01 2007-05-31 Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie ATE457729T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011432A EP1862166A1 (de) 2006-06-01 2006-06-01 Verwendung von Allopurinol zur behandlung von palmar-plantarer Erythrodysesthesie
EP07107744 2007-05-08
PCT/EP2007/055367 WO2007138103A1 (en) 2006-06-01 2007-05-31 Use of allopurinol for the treatment of palmar plantar erythrodysesthesia

Publications (1)

Publication Number Publication Date
ATE457729T1 true ATE457729T1 (de) 2010-03-15

Family

ID=38512579

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07729768T ATE457729T1 (de) 2006-06-01 2007-05-31 Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie

Country Status (21)

Country Link
US (3) US7973046B2 (de)
EP (1) EP2035006B1 (de)
JP (3) JP5028480B2 (de)
KR (1) KR101471022B1 (de)
AT (1) ATE457729T1 (de)
AU (1) AU2007267069B2 (de)
CA (1) CA2654270C (de)
CY (1) CY1110336T1 (de)
DE (1) DE602007004849D1 (de)
DK (1) DK2035006T3 (de)
ES (1) ES2341379T3 (de)
HR (1) HRP20100210T1 (de)
IL (1) IL195472A (de)
MX (1) MX2008015266A (de)
NZ (1) NZ573248A (de)
PL (1) PL2035006T3 (de)
PT (1) PT2035006E (de)
RS (1) RS51252B (de)
RU (1) RU2438673C2 (de)
SI (1) SI2035006T1 (de)
WO (1) WO2007138103A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246057A1 (de) * 2009-04-29 2010-11-03 Nobera Pharma, S.L. Verwendung von Allopurinol zur Behandlung der Hand-Fuß-Hautreaktion
EP2488642B1 (de) 2009-10-16 2015-03-11 Duke University Zusammensetzungen und verfahren zur behandlung des arzneimittelinduzierten hand-fuss-syndroms
EP2368549A1 (de) 2010-03-25 2011-09-28 BioAlliance Pharma Behandlung des Hand-Fuß-Syndroms und zugehöriger Symptome mittels Clonidin oder Derivaten davon
JP4983989B2 (ja) * 2010-03-31 2012-07-25 小野薬品工業株式会社 手足症候群の予防および治療剤
EP2554184B1 (de) 2010-03-31 2016-10-26 ONO Pharmaceutical Co., Ltd. Mittel zur verhinderung und/oder heilung des hand-fuss-syndroms
JP4761000B1 (ja) * 2010-11-08 2011-08-31 小野薬品工業株式会社 手足症候群の予防および／または治療剤
US9259343B2 (en) 2012-07-06 2016-02-16 Newman Technologies LLC Device for mitigating plantar fasciitis
EP2712613B1 (de) * 2012-09-28 2017-02-08 Pharmadab d.o.o. Vitamin K1 und Verwendungen davon
CN108778263A (zh) * 2016-03-28 2018-11-09 维达克制药有限公司 用于局部用药的稳定药物组合物及其用途
WO2019114705A1 (zh) 2017-12-13 2019-06-20 上海小午医药科技有限公司 一种用于预防或治疗与egfr被抑制相关疾病的方法
CN111989095A (zh) 2018-04-16 2020-11-24 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
RU2722396C2 (ru) * 2018-07-11 2020-05-29 Федеральное государственное бюджетное учреждение дополнительного профессионального образования "Центральная государственная медицинская академия" Управления делами Президента Российской Федерации (ФГБУ ДПО "ЦГМА") Способ лечения пальмарно-плантарной эритродизестезии

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3011A (en) * 1843-03-21 Improvement in water-wheels
ES2037672T3 (es) 1987-02-13 1993-07-01 Pharm-Allergan Gmbh Utilizacion de pteridinas y/o purinas o de un inhibidor de xantinoxidasa para la fabricacion de un medicamento para el tratamiento de enfermedades degenerativas de la retina condicionadas geneticamente.
JPH03106817A (ja) 1989-09-20 1991-05-07 Nippon Kayaku Co Ltd アロプリノール製剤
JPH066700A (ja) 1992-06-22 1994-01-14 Fujitsu General Ltd ハイビジョン受像機
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
AU4974893A (en) 1992-09-04 1994-03-29 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
EP1292265B1 (de) 2000-06-20 2007-03-21 Henkel Kommanditgesellschaft auf Aktien Verwendung von Vitamin B6-Derivaten zur Haarstrukturverbesserung
US6685917B2 (en) 2000-11-22 2004-02-03 Rxkinetix, Inc. Treatment of mucositis
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US20050054991A1 (en) * 2001-08-29 2005-03-10 Tobyn Michael John Topical administration device
CA2466869C (en) 2001-11-29 2010-01-19 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DE10200578A1 (de) * 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
WO2004110380A2 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
CA2528359A1 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
US20050148910A1 (en) 2003-12-24 2005-07-07 Gregory Skover Apparatus having a skin-contactable element containing an agent
CA2557814A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
ES2614113T3 (es) * 2004-09-17 2017-05-29 Biomas Ltd. Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta

Also Published As

Publication number Publication date
WO2007138103A1 (en) 2007-12-06
EP2035006B1 (de) 2010-02-17
NZ573248A (en) 2011-01-28
RU2438673C2 (ru) 2012-01-10
DE602007004849D1 (de) 2010-04-01
JP2009542581A (ja) 2009-12-03
DK2035006T3 (da) 2010-04-19
ES2341379T3 (es) 2010-06-18
KR20090031697A (ko) 2009-03-27
IL195472A0 (en) 2011-08-01
MX2008015266A (es) 2009-02-10
AU2007267069B2 (en) 2011-08-11
SI2035006T1 (sl) 2010-04-30
US7973046B2 (en) 2011-07-05
CA2654270C (en) 2014-05-13
HRP20100210T1 (hr) 2010-05-31
RS51252B (sr) 2010-12-31
KR101471022B1 (ko) 2014-12-09
US8557829B2 (en) 2013-10-15
US20090306097A1 (en) 2009-12-10
US20110224237A1 (en) 2011-09-15
CA2654270A1 (en) 2007-12-06
JP5389980B2 (ja) 2014-01-15
JP5028480B2 (ja) 2012-09-19
JP2012180370A (ja) 2012-09-20
CY1110336T1 (el) 2015-01-14
EP2035006A1 (de) 2009-03-18
RU2008152341A (ru) 2010-07-20
PL2035006T3 (pl) 2010-07-30
US20140011820A1 (en) 2014-01-09
JP2014028851A (ja) 2014-02-13
IL195472A (en) 2012-04-30
AU2007267069A1 (en) 2007-12-06
PT2035006E (pt) 2010-04-22

Similar Documents

Publication Publication Date Title
DE602007004849D1 (de) Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie
EA202091303A3 (ru) Композиция ингибитора jak для местного применения
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
ECSP13012618A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
HK1216506A1 (zh) 含硒組合物及其治療和預防與線粒體功能障礙有關的疾病或病症的應用
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
PH12019502334A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
DE602005013793D1 (de) Thiazolderivate mit vap-1-hemmender wirkung
CR10410A (es) Carboxamidas sustituidas.
MX2011011529A (es) Uso de alopurinol para el tratamiento de la reaccion cutanea en manos-pies.
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
NO20075199L (no) Treatment or prevention of pruritus
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
ATE420089T1 (de) Substituierte azachinazoline mit antiviraler wirkung
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
WO2007144889A3 (en) Treatment of neurofibromatosis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2035006

Country of ref document: EP